NMS-293 is under clinical development by Nerviano Medical Sciences and currently in Phase II for Astrocytoma. According to GlobalData, Phase II drugs for Astrocytoma have a 25% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how NMS-293’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

NMS-293 overview

NMS-293 is under development for the treatment of recurrent glioblastoma multiforme (GBM), diffuse astrocytoma, oligodendroglioma, glioblastoma multiforme, metastatic HER2 negative breast cancer, epithelial ovarian cancer, castration-resistant prostate cancer (CRPC) and pancreatic cancer. It is a small molecule. It acts by targeting poly (ADP-ribose) polymerase 1 (PARP-1). The drug candidate is administered through oral route as a hard capsule.

Nerviano Medical Sciences overview

Nerviano Medical Sciences (NMS), a subsidiary of NMS Group SpA, is discovering and developing small molecule NCEs (new chemical entities) for oncology indications. It is primarily focusing on developing inhibitors including encorafenib, for melanoma and colorectal cancer; entrectinib for relapsed/refractory tumors and onvansertib for AML (acute myeloid leukemia) and solid tumors. Its pipeline also includes milciclib and NMS-153 for hepatocellular carcinoma (HCC); NMS-088 for acute myeloid leukemia; and NMS-293 for breast, ovarian, prostate and pancreatic tumors. The company utilizes KINASE and ADC platform technologies to carry out the research and development of its novel treatments. NMS is headquartered in Milan, Lombardy, Italy.

For a complete picture of NMS-293’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 2 September 2023

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.